Arbuthnot Banking Group: 2022 profits and growth in core and new franchises

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

Arbuthnot Banking Group plc (LON:ARBB) 2022 results delivered the expected strong profit and franchise growth (pre-tax profit up from £4.6m to £20m). Core business profitability increased primarily because of widening spreads increasing the value of deposits. Core credit quality remained good. The scale of growth has been driven by the way in which ABG has managed its franchise, building a relationship bank with less price-sensitive deposits. In recent years, Arbuthnot Banking Group has invested in multiple, new, specialised SME financing businesses. These delivered franchise/profit growth in 2022. There is no Silicon Valley Bank (SVB) read-across. The dividend rose by more than expected, and the medium-term Return on Capital (RoC ) target was achieved early.

  • New franchise growth: Asset-Backed Lending profits grew from £4.7m to £5.2m. RAF lending increased from £97m to £134m. Excluding the gain on purchase, Asset Alliance saw losses reduce from £4.8m to £2.1m. Internal funding costs grew by £8.8m, giving a £10m total 2022 “new unit” profit uplift.
  • Balance sheet strength: End-2022 loans were £2.04bn (2021: £1.87bn), and deposits were £3.09bn (2021: £2.84bn). Unlike SVB, surplus liquidity is deployed primarily in accounts with the Bank of England (£0.7bn), and not in mis-matched duration government bonds. The total capital ratio was 14.0% (2021: 14.9%).
  • Valuation: Our multiple approaches see a broad range of valuations: £11.58 DDM, £27.46 SOTP and £23.15 GGM. The average is £20.73, up from £16.67, reflecting the results, and moving forward the base year. Trading at 66% of NAV is anomalous with above cost of capital returns.
  • Risks: The trend, and level, of interest rates will determine short-term profitability. Credit is a risk, but all the metrics remain positive. ABG is very conservative in lending. Its financial strength means that it can take time to optimise recoveries. Other risks include reputation, regulation and compliance.
  • Investment summary: Arbuthnot Banking Group offers strong-franchise and continuing-business (normalised) profit growth. Its balance sheet strength gives it a number of wide-ranging options to develop organic and inorganic opportunities. The latter are likely to increase in uncertain times. Management has been innovative, but also very conservative, in managing risk. Having a profitable, well-funded, well-capitalised and strongly growing bank priced below book value is an anomaly.
Share on:
Find more news, interviews, share price & company profile here for:

If our articles help you then why not add us as a preferred news source on Google.

Higher bond yields sharpen the focus on AI and asset allocation

Higher bond yields and a shift towards AI software are changing market positioning as investors weigh resilient growth against persistent inflation and debt supply.

Shakespeare Monofilament acquisition secures £5.92m asset-based funding package

Nova Capital Management’s acquisition of Shakespeare Monofilament UK is supported by a £5.92 million asset-based lending package spanning receivables, inventory, machinery and property.

Arbuthnot Latham launches cross-border investment service for US-connected UK clients

Arbuthnot Latham has launched Global Direct Service for US-connected UK clients, adding a direct-investment option to its private banking and wealth management offering.

AI spending comes under pressure as markets demand clearer returns

Markets are shifting their focus from the scale of AI spending to the returns it can generate as interest rates and competition remain key risks.

Arbuthnot Banking Group reports record deposits and wealth assets (LON:ARBB)

Hardman & Co analyst Mark Thomas discusses Arbuthnot Banking Group’s first-half 2026 results, highlighting record client balances, strong growth across deposits, wealth management and specialist lending, and the potential benefit of higher-for-longer interest rates.

Nova Capital backs Shakespeare Monofilament acquisition with £5.92m funding package

Nova Capital’s acquisition gives Shakespeare new ownership and a £5.92 million funding structure designed to support working capital and future development.

Search

Search